The groundbreaking success of the copyright undeniably reshaped the medication landscape, but investing in companies heavily reliant on off-patent versions presents a complex picture. Despite early returns were impressive, the cessation of patents and the appearance of discounted alternatives have weakened the customer base. Thus, a thorough evalua